Press Releases

Press Releases

SAN FRANCISCO and HERZLIYA, Israel, Nov. 11, 2019 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing
11/11/2019
SAN FRANCISCO and HERZLIYA, Israel, Jan. 3, 2019 /PRNewswire/ -- 89bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today announced the appointment of Hank Mansbach, M.D., as chief medical officer.  Dr.
01/03/2019